Inhaled PGE(1) in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials

BACKGROUND: Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of infants. Aerosolized prostaglandins I(2) (PGI(2)) and E(1) (PGE(1)) have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Sood, Beena G, Keszler, Martin, Garg, Meena, Klein, Jonathan M, Ohls, Robin, Ambalavanan, Namasivayam, Cotten, C Michael, Malian, Monica, Sanchez, Pablo J, Lakshminrusimha, Satyan, Nelin, Leif D, Van Meurs, Krisa P, Bara, Rebecca, Saha, Shampa, Das, Abhik, Wallace, Dennis, Higgins, Rosemary D, Shankaran, Seetha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414424/
https://www.ncbi.nlm.nih.gov/pubmed/25496504
http://dx.doi.org/10.1186/1745-6215-15-486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414424/
https://www.ncbi.nlm.nih.gov/pubmed/25496504
http://dx.doi.org/10.1186/1745-6215-15-486

Ejemplares similares